[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetes-mellitus---type-2\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetes-mellitus---type-2":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100623850","phase-4-effects-of-semaglutide-on-clinical-outcomes-and-metabolic-inflammation-in-psoriasis-100623850",false,"NCT07401992","Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis","Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis: A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial","SEMAPSO","Inclusion Criteria:\n\n* Male or female participants aged ≥18 years at the time of randomization.\n* Clinical diagnosis of plaque psoriasis with Psoriasis Area and Severity Index (PASI) ≥3 and body surface area (BSA) ≥3%.\n* Body mass index (BMI) ≥25 kg\u002Fm², consistent with overweight or obesity.\n* Participants with or without type 2 diabetes mellitus.\n* Participants with diabetes must be on stable antidiabetic therapy (no changes in medication or dosage within the previous 3 months) and have adequate glycemic control, defined as HbA1c ≤9.0% at baseline.\n* No use of systemic psoriasis therapies (e.g., methotrexate, cyclosporine) for at least 8 weeks prior to randomization.\n* No use of biologic therapies for at least 3 months prior to randomization.\n\nExclusion Criteria:\n\n* Diagnosis of a non-plaque psoriasis subtype, including pustular, guttate, nail, inverse, psoriatic arthritis, or erythrodermic psoriasis.\n* Pregnancy or breastfeeding at the time of screening or enrollment.\n* Insulin-dependent diabetes mellitus or current use of sulfonylureas.\n* Active malignancy at the time of screening.\n* History of thyroid neoplasia.\n* Presence of autoimmune diseases.\n* Use of systemic therapies within 8 weeks prior to randomization.\n* Use of biologic therapies within 3 months prior to randomization.\n* Renal insufficiency.\n* Heart failure.\n* Hepatic insufficiency.\n* History of pancreatitis.\n* Current treatment with other GLP-1 receptor agonists.\n* History of inflammatory bowel disease.\n* Known allergy to starch.","ALL","18 Years",{"count":20,"type":21},62,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study will evaluate the effects of oral semaglutide in combination with topical corticosteroid\u002Fcalcipotriol on clinical outcomes and metabolic inflammation in patients with plaque psoriasis and overweight\u002Fobesity and\u002For type 2 diabetes mellitus. A total of 62 participants will be randomized to receive either semaglutide plus topical corticosteroid\u002Fcalcipotriol or placebo plus topical corticosteroid\u002Fcalcipotriol for 12 weeks. Clinical efficacy will be assessed using the Psoriasis Area and Severity Index (PASI), and quality of life will be evaluated using DLQI, PROMIS-29, and EQ-5D-5L. Systemic inflammatory markers will also be measured to assess metabolic inflammation.",[27,28,29],"Psoriasis (PsO)","Obesity & Overweight","Diabetes Mellitus - Type 2",[31,32,33,34,35,36,37,38],"clinical trial","psoriasis","dermatology","semaglutide","GLP-1","obesity","overweight","diabetes","RECRUITING","2026-02-03",{"date":42,"type":43},"2026-02-11","ACTUAL",{"date":45,"type":43},"2026-01-15",{"date":47,"type":21},"2027-02-28",{"name":49,"class":50},"Hospital Universitario Dr. Jose E. Gonzalez","OTHER"]